Explore
For Enterprise
Join for Free
Log In

Arts and Humanities
Business
Computer Science
Data Science
Information Technology
Health
Math and Logic
Personal Development
Physical Science and Engineering
Social Sciences
Language Learning
Degrees
Certificates

Explore all of Coursera

Browse
Search
For Enterprise
Log In
Join for Free

7.3 Hypermethylation of sets of CpG islands in cancer

Loading...

Epigenetic Control of Gene Expression

The University of Melbourne

4.8 (474 ratings) | 30K Students Enrolled

While the human genome sequence has transformed our understanding of human biology, it isn’t just the sequence of your DNA that matters, but also how you use it! How are some genes activated and others are silenced? How is this controlled? The answer is epigenetics. Epigenetics has been a hot topic for research over the past decade as it has become clear that aberrant epigenetic control contributes to disease (particularly to cancer). Epigenetic alterations are heritable through cell division, and in some instances are able to behave similarly to mutations in terms of their stability. Importantly, unlike genetic mutations, epigenetic modifications are reversible and therefore have the potential to be manipulated therapeutically. It has also become clear in recent years that epigenetic modifications are sensitive to the environment (for example diet), which has sparked a large amount of public debate and research. This course will give an introduction to the fundamentals of epigenetic control. We will examine epigenetic phenomena that are manifestations of epigenetic control in several organisms, with a focus on mammals. We will examine the interplay between epigenetic control and the environment and finally the role of aberrant epigenetic control in disease. All necessary information will be covered in the lectures, and recommended and required readings will be provided. There are no additional required texts for this course. For those interested, additional information can be obtained in the following textbook. Epigenetics. Allis, Jenuwein, Reinberg and Caparros. Cold Spring Harbour Laboratory Press. ISBN-13: 978-0879697242 | Edition: 1

Skills You'll Learn

Cancer, Molecular Biology, Cancer Epigenetics, Dna Methylation

Reviews

4.8 (474 ratings)

5 stars
408 ratings
4 stars
60 ratings
3 stars
3 ratings
2 stars
1 ratings
1 star
2 ratings

BM

Aug 14, 2017

One of the best organized and implemented courses I have taken so far. For someone who had barely any experience with epigenetics, I feel this gave me a proper introduction to the field.

HH

Dec 18, 2016

A quintessential course for Genetics students all over the world. Very nicely prepared and elucidated by Dr. Marnie Blewitt .\n\nMany many thanks to Dr. Marnie Blewitt & Coursera team.

From the lesson

Week 7 - Cancer Epigenetics

This week we’ll bring together much of what we’ve learned in previous weeks of the course, to understand how the epigenome is affected, and can also affect, cancer development and progression. We’ll then go on to discuss the potential therapeutic benefits that can come from using epigenetic biomarkers, and targeting epigenetic modifiers in cancer.

7.1 Overview of cancer epigenetics7:13

7.2 Hypermethylation of CpG islands in cancer16:40

7.3 Hypermethylation of sets of CpG islands in cancer11:59

7.4 Hypomethylation genome-wide in cancer12:04

7.5 Altered histone modifications in cancer11:55

7.6 Long range epigenetic alterations in cancer and alterations to nuclear architecture10:25

7.7 Altered expression on piRNAs and long noncoding RNAs in cancer9:35

7.8 Mutations in epigenetic modifiers in cancer9:41

7.9 Drugs that target the epigenetic machinery as chemotherapeutics17:05

7.10 Extension lecture: Aging - Part 114:07

7.11 Extension lecture: Aging - Part 223:04

Taught By

Dr. Marnie Blewitt
Head, Molecular Medicine Laboratory

Transcript

So in the last lecture we thought about hypermethylation and how single gene

biomarkers could be used prognostically, diagnostically and to alter

treatment outcome. But now we're going to think about how

you can have hypermethylation and measure hypermethylation of sets of genes or

panels of genes and how these might be useful.

Want to start out by telling you about a particular tumour type called CpG island

methylator phenotype, CIMP, as a way of describing the

hypermethylation of sets of genes and what it might mean.

So these cancers, these have got more than you would expect.

So, higher levels of CpG island hypermethylation than you would see in

general in cancers. And so this methylated phenotype, has

been, has been called CIMP in the literature.

So, this frequent occurrence of hypermethylation has been described for

several different types of cancers. It was first described for colorectal cancer.

Later for glioma, more recently for

neuroblastoma and many more. So in each of these cases we know that

although in, for each of the tumour types you see hypermethylation.

That's very frequent, hypermethalation of CpG islands, that's quite common in them

and perhaps more so than in other tumours.

The actually sets of CpG's that are hypermethylated differ by tumour type.

So colorectal cancer won't necessarily have the same set of CpG islands that are

hypermethylated as you see in glioma, for example.

So why would we care if they are particular cancers that have this

hypermethylation phenotype, this methylated phenotype or CIMP?

Well, as usual with cancer, the reason that we care is because these types of

tumours are clinically different. They're clinically distinct and

therefore, alter the way that they can be interpreted by the doctors, and therefore

the outcome for the patients. So, if we start out with Colorectal

cancer. And just think about Colorectal CIMP,

because this is where we know them most. It was when it was earliest described for

the first time. We know that in general in these

patients, they tend to be of older patient age, they're mostly females.

They tend to have defective MLH1 function, this mismatch repair gene which

I've told you about with regard to Lynch syndrome.

The tumours tend to be in the ascending colon.

They even have a particular place that they occur in the colon.

And importantly, they have good prognostic outcome.

So, if you can diagnose a person as having CIMP then you can tell them that

they are that you can infer that they are likely to have a good outcome, and this

is really important for patients. But also these clinically distinct

phenotypes, these clinically distinct features of CIMP suggest that perhaps

some particular epigenetic therapy would be useful in these cases.

So just like we spoke about single bio markers in terms of being useful for

diagnosis and prognosis and for monitoring panels of bio markers are also

very useful in this way. So where single genes can be very useful

if they're are a perfect bio marker if you like.

if you have panels of bio markers, each individual bio marker may not be as

strong as say MGMT was for determining whether temozolomide would work, or GSTP1

in the prostate. But each of them can be slightly less

efficient or slightly less sensitive, but as a panel you can have overall they'll

end up giving you a very efficient and very sensitive, read out of where the

situation is occurring. So, they're now becoming more

commonly used, and more commonly these panels of biomarkers are being put

together so that you can still have useful diagnostic information, for example.

So, with these panels of biomarkers, you

might be able to identify a tumour type. Say, for example, be able to determine

that it was a CIMP tumour, because of the level of hypermethylation. How

frequently hypermethylation occurred. So other than just tumour type you may

also be able to look tumour sub type. So because of these genome wide studies

which I mentioned earlier that have occurred for DNA methylation, we now know

it's been fairly recent data where they can actually say let's look genome wide at the where

the CPG islands are hypermethylated. And they find it's not just possible to

say this is a CIMP tumour or not. But rather, you're able to say this is

this particular tumour sub type. And so if you stratify each of the tumours

based on their methylation profile, genome wide,

you can very, very accurately determine which sub type of a tumour is found.

And what's intriguing is that this

definition of which sub-type you have is perhaps more efficient when using DNA

methylation biomarkers than if you use gene expression.

So that's intriguing because you would imagine that the DNA methylation marks

would be just mirrored by gene expression, but indeed perhaps not all of

these methylation markers are mirrored by gene expression and therefore DNA

methylation ends up being a little more powerful.

So, what I think is perhaps one of the most interesting uses of having a panel

of biomarkers, is that in patients where they don't actually know what their

original tumour is, you might be able to work out what their primary tumour was.

So, and to my mind, if you think about it naively,

you think that probably everybody would know what their primary tumour was.

But this isn't in fact the case. There are a large number of patients that

present each year in any country around the world where they don't

necessarily know what the primary tumour was.

By the time they've been ill enough to come and present to a doctor they already

have metastasis, so clinically it's very important to work out which was the

primary tumour and which the metastasis. Because it's the primary tumour that will

usually define the type of treatment that will be required.

And the metastases will relate to that primary tumour.

So say for example, if the primary tumour was in a location where you wouldn't

detect a lump. Or you wouldn't necessarily begin to feel

ill quickly, it will often have metasicised before you felt sick enough

to go to the doctor. So in these cases, it's very useful to be

able to work out what that primary tumour was.

We also know that these panels of biomarkers just like detecting which

particular cancer it is, whether its a particular cancer subtype for diagnosis,

can be useful for prognosis. So, while I've mentioned that CIMP has a

favourable prognostic outcome. It tends to have a very good outcome.

The patients respond well to treatment. High methylation in other cancers for

example myelodysplastic syndrome this is found in the blood.

It's of the myeloid cells. Or lung cancer.

High methylation in both of these cases has a poor prognostic outcome.

And this is perhaps what you'd expect based on what I said about how the

methylation progresses over time. And so each of these are important

measures to make. And finally, as I've mentioned before, by

using single biomarkers or indeed panels of biomarkers, you're able to monitor the

tumour burden, or measure whether the tumour is declining or perhaps again

recurring again over time. And this is because of the cell free DNA

or because of tumour cells that can be found in the blood and easily monitored.

And again, as I mentioned just before, if you use panels of biomarkers, you are

more sensitive to be able to detect this more accurately as opposed to a

single biomarker. So, while we in general have

hypermethylation of CpG islands associated with tumour suppressors, it is

the most common type of hypermethylation found in tumour cells.

What's been recently discovered is you also have hypermethylation of the regions

surrounding those CpG islands. These are called the CpG island shores.

So, if you imagine that your CpG island is in a certain block and this is, tends

to be unmethylated but in a tumour cell will be methylated.

The regions surrounding the CpG island. The 2 kilobases upstream or downstream.

It's been recently discovered that although they don't have the same density

of CpGs, therefore they're not still considered the island, they are also

hypermethylated in cancer. So, this has also been shown in normal cells.

So in normal cells, the methylation at

the promoter can predict whether or not a gene will be expressed or not.

So if, if a promoter is hypermethylated, its unlikely to be expressed.

It's not necessarily true that a hypomethylated promoter will be

expressed, but if it's hypermethylated, it's highly unlikely to be expressed.

And it's known now that this methylation actually does indeed spread to these

shore regions. This happens both in normal cells and in cancer.

What's interesting again is that if you

correlate the hypermethylation at the shores rather than just at the CpG

island, this perhaps correlates even better with gene expression than CpG island

methylation itself. And so this leads to the

possibility that perhaps although I've told you these biomarkers that are at the

CpG islands are actually really good, maybe in the future we'll be able to do

even better. So the final sort of hypermethylation I

want to mention in the context of cancer is hypermethylation of imprint control regions.

So one of the really common features of

cancer cells is they display loss of imprinting.

So in other words, genes that should be displaying monoallelic

parent-of-origin-specific expression, in other words, they're imprinted, no longer

show this imprinted expression but rather they become either expressed from

both parental alleles or silent from both parental alleles.

And the reason this is found in cancer is probably because lots of genes that are

imprinted are involved in growth - in some way.

Either they're growth promoting or growth suppressing.

So we don't exclusively find hypermethylation of imprint control

regions in cancer. You can also find hypomethylation of

imprint control regions, and this of course depends on the particular imprint

control region you're looking at and the function of the genes that are found

within the controlled region. But in this case I just want to mention

the hypermethylation of imprint control regions with one specific example.

But keep in mind that either can occur in fact, that we can have hypermethylation

in some instances. And hypomethylation in other imprint

control regions. So if you think back to the Igf2H19

cluster that we spoke about in week 4, we know here, here is the imprint control

region shown as the oval. And it's methylated on the paternal

allele, and it's unmethylated on the maternal allele.

When it's unmethylated CTCF will binds this insulator element, and it means that the

enhancers in this case will act on H19. But Igf2 will be silent for the maternal

allele, so we don't see expression. On the paternal allele, because this is

methylated, now the enhancers can act on Igf2, because CTCF is not

binding to insulate this, and IGF2 is expressed from the paternal allele.

However, with loss of imprinting and what happened is you have hypermethylation

of the imprint control region on the maternal allele as well,

now, on the maternal allele, you also have expression of Igf2.

So now you have a double dose of Igf2 in comparison to what you saw in a normal cell.

And Igf2 is growth promoting, and

this is associated with Wilms’ tumour. This is this particular childhood kidney

tumour that is observed. So, while I'm showing you this for this

one specific example, loss of imprinting is observed in a very wide array of tumour types.

And in fact, occurs as a very early

event, so it's often seen in preneoplastic tissues.

So, before you would actually decide that it really was a frank tumour.

And so this suggests that maybe these events at the imprint control regions,

these hypermethylation, or hypomethylation events

might be very early events in tumourogenesis.

So, we've now covered hypermethlyation in the context of cancer and in the next

lecture we'll think about hypomethylation that's observed so the less methylation

that you'd expect which is found genome wide.

Explore our Catalog

Join for free and get personalized recommendations, updates and offers.

Coursera provides universal access to the world’s best education, partnering with top universities and organizations to offer courses online.

© 2019 Coursera Inc. All rights reserved.

Download on the App Store

Get it on Google Play

Coursera
About
Leadership
Careers
Catalog
Certificates
MasterTrack™ Certificates
Degrees
For Enterprise
For Government

Community
Learners
Partners
Developers
Beta Testers
Translators

Connect
Blog
Facebook
LinkedIn
Twitter
Instagram
YouTube
Tech Blog

More
Terms
Privacy
Help
Accessibility
Press
Contact
Directory
Affiliates